BioWorld

Nov. 10, 2009

Enzon Offloads Specialty Arm to Sigma-Tau for up to $327M

Enzon Pharmaceuticals Inc. has agreed to sell its specialty pharmaceutical business to Italian-owned Sigma-Tau Pharmaceuticals Inc. for $300 million plus up to an additional $27 million based on milestones. (BioWorld Today) Read More

Trius and Alimera Join Growing Roster of Biotech IPO Hopefuls

Twists and Turns Still Ahead for Health Reform after House Vote

D-Pharm Taking Stroke Drug into China with $25.5M Deal

Clinic Roundup

Other News To Note

ACAAI Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...